Compare Stocks

→ The Gold Grab of the Century (From Colonial Metals) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADDXF Addex Therapeutics	$0.99	$0.99	$0.99 ▼ $0.99	N/A	0.25	N/A	N/A
ASLN ASLAN Pharmaceuticals	$0.44 -1.8%	$0.60	$0.39 ▼ $4.69	$7.19M	1.45	982,203 shs	109,904 shs
CALA Calithera Biosciences	$0.02 -31.0%	$0.02	$0.01 ▼ $0.50	$97K	-0.17	1,535 shs	249 shs
FWP Forward Pharma A/S	$1.95	$2.17	$1.50 ▼ $6.48	$13.83M	1.38	7,484 shs	N/A
HUGE FSD Pharma	$0.49 +3.1%	$0.72	$0.42 ▼ $1.68	$19.19M	0.59	144,661 shs	63,047 shs

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADDXF Addex Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
ASLN ASLAN Pharmaceuticals	-4.68%	-17.04%	-29.45%	-25.21%	-89.32%
CALA Calithera Biosciences	-31.03%	-20.16%	0.00%	-33.33%	-52.61%
FWP Forward Pharma A/S	0.00%	0.00%	0.00%	0.00%	0.00%
HUGE FSD Pharma	+3.01%	+1.98%	-32.56%	-44.17%	-67.17%

Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (Ad)

Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.

Click here for your free guide

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADDXF Addex Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ASLN ASLAN Pharmaceuticals	2.2843 of 5 stars	3.5	3.0	0.0	0.0	2.9	0.8	0.6
CALA Calithera Biosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
FWP Forward Pharma A/S	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
HUGE FSD Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADDXF Addex Therapeutics	N/A	N/A	N/A	N/A
ASLN ASLAN Pharmaceuticals	3.00	Buy	$11.33	2,475.76% Upside
CALA Calithera Biosciences	N/A	N/A	N/A	N/A
FWP Forward Pharma A/S	N/A	N/A	N/A	N/A
HUGE FSD Pharma	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest ASLN, ADDXF, CALA, HUGE, and FWP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/23/2024	ASLN ASLAN Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
4/15/2024	ASLN ASLAN Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
3/18/2024	ASLN ASLAN Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$17.00 ➝ $9.00
3/13/2024	ASLN ASLAN Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$15.00 ➝ $10.00

(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADDXF Addex Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
ASLN ASLAN Pharmaceuticals	$12M	0.60	N/A	N/A	($0.81) per share	-0.54
CALA Calithera Biosciences	$9.75M	0.01	N/A	N/A	($0.40) per share	-0.05
FWP Forward Pharma A/S	N/A	N/A	N/A	N/A	$10.09 per share	N/A
HUGE FSD Pharma	N/A	N/A	N/A	N/A	$0.33 per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADDXF Addex Therapeutics	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
ASLN ASLAN Pharmaceuticals	-$44.22M	-$2.74	N/A	N/A	N/A	N/A	-8,454.87%	-95.72%	4/26/2024 (Estimated)
CALA Calithera Biosciences	-$39.65M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
FWP Forward Pharma A/S	-$1.89M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
HUGE FSD Pharma	-$17.90M	-$0.47	N/A	∞	N/A	N/A	-112.38%	-82.46%	5/10/2024 (Estimated)

Latest ASLN, ADDXF, CALA, HUGE, and FWP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
4/26/2024	N/A	ASLN ASLAN Pharmaceuticals	N/A	-$0.61	-$0.61	N/A	N/A	N/A
4/12/2024	Q4 2023	ASLN ASLAN Pharmaceuticals	N/A	-$0.78	-$0.78	-$0.78	N/A	N/A
3/28/2024	Q4 2023	HUGE FSD Pharma	N/A	-$0.04	-$0.04	-$0.04	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADDXF Addex Therapeutics	N/A	N/A	N/A	N/A	N/A
ASLN ASLAN Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CALA Calithera Biosciences	N/A	N/A	N/A	N/A	N/A
FWP Forward Pharma A/S	N/A	N/A	N/A	N/A	N/A
HUGE FSD Pharma	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADDXF Addex Therapeutics	N/A	N/A	N/A
ASLN ASLAN Pharmaceuticals	N/A	1.84	1.84
CALA Calithera Biosciences	N/A	N/A	N/A
FWP Forward Pharma A/S	N/A	18.43	N/A
HUGE FSD Pharma	N/A	2.43	2.43

Ownership

Institutional Ownership

Company	Institutional Ownership
ADDXF Addex Therapeutics	N/A
ASLN ASLAN Pharmaceuticals	58.82%
CALA Calithera Biosciences	N/A
FWP Forward Pharma A/S	12.57%
HUGE FSD Pharma	1.24%

Insider Ownership

Company	Insider Ownership
ADDXF Addex Therapeutics	N/A
ASLN ASLAN Pharmaceuticals	4.69%
CALA Calithera Biosciences	6.60%
FWP Forward Pharma A/S	71.47%
HUGE FSD Pharma	8.53%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ADDXF Addex Therapeutics	26	N/A	N/A	Not Optionable
ASLN ASLAN Pharmaceuticals	35	16.35 million	15.58 million	Optionable
CALA Calithera Biosciences	8	4.87 million	4.55 million	Not Optionable
FWP Forward Pharma A/S	4	7.09 million	2.02 million	Not Optionable
HUGE FSD Pharma	17	39.38 million	36.02 million	Optionable

ASLN, ADDXF, CALA, HUGE, and FWP Headlines

Source	Headline
	FSD Pharma Provides Update from Celly Nu's Partnership with Six+One for unbuzzd(TM) accesswire.com - April 25 at 7:47 AM
	US to provide 'significant' new security assistance for Ukraine, Biden tells Zelenskiy finance.yahoo.com - April 23 at 8:57 PM
	I’m a doctor in Haiti. Crisis may be death sentence for many with health problems \| Opinion news.yahoo.com - April 23 at 8:57 PM
	Future Tesla FSD Will Merge and Expand with XAI Grok nextbigfuture.com - April 23 at 3:34 AM
	FSD Pharma (NASDAQ:HUGE) Stock Price Up 4.8% americanbankingnews.com - April 23 at 2:16 AM
	FSD Pharma Inc.: FSD Pharma Provides Another Update on Celly Nu's Anticipated Launch of unbuzzd finanznachrichten.de - April 22 at 12:33 PM
	FSD Pharma Provides Another Update on Celly Nu's Anticipated Launch of unbuzzd(TM) accesswire.com - April 22 at 8:00 AM
	Saudi Arabia Earns Top Marks in Global AI Index for National Strategy msn.com - April 18 at 5:45 PM
	Tesla Stock: Plunging Toward My Price Target seekingalpha.com - April 18 at 5:45 PM
	FSD Pharma boosts loan to Celly Nutrition for new beverage uk.investing.com - April 17 at 10:32 AM
	FSD Pharma Expands Investigative Pipeline to Include Potential Weight Loss and Liver Health Formulations and Products accesswire.com - April 17 at 8:00 AM
	FSD Pharma Provides Update on its Investment in Celly Nutrition Corp., a Company Launching a Product that can assist in Expediting Alcohol Metabolism and Faster Recovery from Alcohol Consumption accesswire.com - April 15 at 8:00 AM
	Tesla markets its FSD V12 with impressive real-world results msn.com - April 8 at 10:26 AM
	FSD Pharma Inc. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency newsfilecorp.com - April 7 at 10:55 PM
	Will Good FSD Overcome Bad Deliveries in Q2? nextbigfuture.com - April 2 at 6:11 PM
	FSD Pharma Announces Filing of Year-End 2023 Results accesswire.com - April 1 at 10:00 PM
	Walgreens’ frail quarter goes beyond the discretionary spending dips afflicting its competitors. It’s ‘just not very good at retailing,’ analyst says msn.com - March 29 at 6:32 PM
	Tesla stock slips as analysts issue a fresh round of warnings on Q1 deliveries msn.com - March 28 at 12:29 PM
	How does AI make Tesla FSD 12.3 human like? Deep Dive Analysis nextbigfuture.com - March 28 at 12:29 PM
	FSD Pharma Signs the Agreement With iNGENu CRO To… pharmiweb.com - March 27 at 12:15 PM
	FSD Pharma Signs the Agreement With iNGENu CRO To Conduct a Clinical Study To Assess the Safety and Pharmacokinetics of Multiple Ascending Doses of Lucid-21-302 (Lucid-MS) in Healthy Adults accesswire.com - March 27 at 8:00 AM
	“Decarb army” targets self driving electric utes, heat pumps and saving energy reneweconomy.com.au - March 18 at 1:42 AM
	Psychedelics Headlines: Substitution Survey, Frank Herbert's Magic Mushrooms, Celestial Plans And News Review benzinga.com - March 16 at 1:16 PM
	Big Pharma sent massive payments to NIH during COVID-19 pandemic, watchdog finds 13wham.com - March 15 at 11:03 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Addex Therapeutics

OTCMKTS:ADDXF

Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The Charcot-Marie-Tooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.

ASLAN Pharmaceuticals

NASDAQ:ASLN

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal antibody that targets the IL-13 receptor a1 subunit which is being developed for the treatment of atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune diseases. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.

Calithera Biosciences

NASDAQ:CALA

Calithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.

Forward Pharma A/S

NASDAQ:FWP

Forward Pharma A/S does not have significant operations. Previously, it operated as a biopharmaceutical company that focused on developing FP187 proprietary formulation of dimethyl fumarate for the treatment of inflammatory and neurological indications. Forward Pharma A/S was incorporated in 2005 and is headquartered in Copenhagen, Denmark.

FSD Pharma

NASDAQ:HUGE

FSD Pharma Inc., a biotechnology company, operates in the pharmaceutical research and development business. Its lead candidate is FSD-201, an ultra-micronized palmitoylethanolamide for the treatment of inflammatory diseases. The company is also involved in the research and development of Lucid-Psych, a molecular compound identified for the treatment of mental health disorders; and Lucid-MS, a molecular compound identified for the treatment of neurodegenerative disorders. FSD Pharma Inc. was incorporated in 1998 and is headquartered in Toronto, Canada.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial